

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/037,182	12	2/21/2001	Karl Tryggvason	99,274-F	8557
20306	7590	03/01/2004		EXAMINER	
MCDONNE 300 SOUTH		HNEN HULBI	CARLSON, KAREN C		
SUITE 3200	WACKER	DRIVE	ART UNIT	PAPER NUMBER	
CHICAGO,	IL 60606			1653	

DATE MAILED: 03/01/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/037,182	TRYGGVASON ET AL.				
Office Action Summary	Examiner	Art Unit				
	Karen Cochrane Carlson, Ph.D.	1653				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	rely filed s will be considered timely. the mailing date of this communication. (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
2a) ☐ This action is FINAL . 2b) ☐ This	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) 1-23 is/are pending in the application.						
4a) Of the above claim(s) is/are withdray						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.	·					
7) Claim(s) is/are objected to.						
8) Claim(s) 1-23 are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) □ acc	epted or b) \square objected to by the	Examiner.				
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is ob	jected to. See 37 CFR 1.121(d).				
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)-(d) or (f).				
, , ,	s have been received					
1. Certified copies of the priority document		ion No.				
1. Certified copies of the priority document2. Certified copies of the priority document	s have been received in Applicati					
1. Certified copies of the priority document	s have been received in Applicati rity documents have been receive					
 Certified copies of the priority document Certified copies of the priority document Copies of the certified copies of the priority 	s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ed in this National Stage				
 Certified copies of the priority document Certified copies of the priority document Copies of the certified copies of the priority application from the International Bureau 	s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ed in this National Stage				
 Certified copies of the priority document Certified copies of the priority document Copies of the certified copies of the priority application from the International Bureau 	s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ed in this National Stage				
1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list Attachment(s)	s have been received in Application of the certified copies not received in Application (PCT Rule 17.2(a)). of the certified copies not received	ed in this National Stage				
 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list 	s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ed in this National Stage ed. (PTO-413)				

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-4 and 11-16, drawn to host cells expressing laminin 10, classified in class
 435, subclass 252.3.
- II. Claims 5-10, 17, and 23, drawn to laminin 10, classified in class 530, subclass 350.
- III. Claims 18 and 19, drawn to an improved medical device comprising laminin 10, classified in class 514, subclass 2.
- IV. Claims 20 and 21, drawn to an improved cell growth substrate, classified in class514, subclass 2.
- Claims 22, drawn to a method to accelerate healing of vascular tissue via laminin
 classified in class 514, subclass 2.

The inventions are distinct, each from the other because of the following reasons:

The cells of Invention I are related to the protein of Invention II by virtue of encoding same. The DNA molecule has utility for the recombinant production of the protein in a host cell, as recited in the Claims of Invention I. Although the DNA molecule and protein are related since the DNA encodes the specifically claimed protein, they are distinct inventions because the protein product can be made by another and materially different process, such as by synthetic peptide synthesis or purification from the natural source. Further, the DNA may be used for processes other than the production of the protein, such as nucleic acid hybridization assay.

Inventions I and Inventions III, IV, and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process such as in any one of Inventions III, IV, or V.

Application/Control Number: 10/037,182

Art Unit: 1653

The product of Invention I is not used in the methods of Inventions III, IV, or V. Therefore, Invention I is patentably distinct from Inventions III, IV, and V.

Page 3

The methods of Inventions III, IV, and V are related in that each method requires the use of Invention I. However, the steps and end points of the methods are wholly different and therefore Inventions Inventions III, IV, and V are patentably distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Application/Control Number: 10/037,182

Art Unit: 1653

application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 571-272-0946. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 4